Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A serum protein called REG3-alpha may predict complicated Crohn's disease up to 10 years before diagnosis — even when standard tests like CRP and endoscopy look normal. In two prospective cohorts, high REG3-alpha levels were strongly linked to disease progression, including hospitalizations, surgeries, and new biologic use. This could open the door to earlier, more targeted risk stratification in Crohn's patients.
A protein called REG3-alpha — produced by specialized gut cells called Paneth cells — may be the early warning signal clinicians have been waiting for in Crohn's disease (CD). New research published in Clinical Gastroenterology and Hepatology found that elevated serum REG3-alpha levels predicted disease progression and complicated CD outcomes across two large prospective cohorts, independently of standard markers like CRP and endoscopy.
What makes this especially notable: REG3-alpha flagged risk even in patients with mild or inactive disease. In a separate prediagnostic cohort, elevated levels were detectable up to 10 years before a CD diagnosis — with the highest levels seen in those who went on to develop the most severe disease. Single-cell RNA sequencing also revealed that CD shifts Paneth cells toward inflammatory, hypersecretory subtypes even in non-inflamed tissue, offering a biological explanation for the findings.
Why it matters: Current tools often miss patients at risk for severe CD until disease has already progressed. REG3-alpha could enable earlier, more targeted interventions — potentially preventing surgeries, hospitalizations, and irreversible bowel damage.
